Conference
THU0153 Pregnancy Outcomes in Women Exposed to the Tumor Necrosis Factor Inhibitor, Golimumab
Abstract
Background Rheumatologic conditions and inflammatory bowel disease can affect women of childbearing potential. Golimumab (GLM) is approved for the treatment of rheumatoid arthritis (RA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and ulcerative colitis (UC). GLM should be used during pregnancy only if clearly needed. For RA patients and some PsA patients, GLM is administered with methotrexate (MTX), an agent with teratogenic and …
Authors
Lau A; Clark M; Harrison DD; Geldhof A; Nissinen R; Sanders M
Volume
73
Pagination
pp. 232-233
Publisher
Elsevier
Publication Date
June 2014
DOI
10.1136/annrheumdis-2014-eular.4415
Conference proceedings
Annals of the Rheumatic Diseases
ISSN
0003-4967